Business Wire

Mindpeak Announces CE-IVD Mark for Artificial Intelligence Breast Cancer Cell Quantification

Share

Mindpeak, a European leader in computational pathology, announced today that it has received CE-IVD Mark for BreastIHC, an Artificial Intelligence software that detects and quantifies breast cancer cells, for primary diagnosis. The CE-IVD Mark makes the software available to pathology practices across Europe and helps overcome the challenge of an increasing demand for cancer diagnostics.

Hamburg, Germany based Mindpeak is the first company to receive approval for a Deep Learning solution which can distinguish between tumorous and non-tumorous structures on a cellular level. The CE-IVD Mark for in-vitro-diagnostic medical devices confirms that BreastIHC complies with all essential health and safety requirements of all applicable EU directives. "We are very excited about the CE Mark as it allows us to empower pathologists to gain efficiency and increased accuracy in primary diagnosis", explains Mindpeak CEO and founder Felix Faber.

The detection and quantification of immunohistochemically stained breast tumor cells is one of the most critical tasks for a pathologist as the diagnosis directly impacts the treatment decision for the patient. The task itself is - without AI Support - tedious and error prone, also a result of the increasing pressure pathologists are exposed to due to an increasing number of cancer cases. Studies show that even the best pathologists differ in diagnosis in a significant proportion of patients which can be up to a fifth of cases1.

BreastIHC is a plug-and-play solution that enables pathology laboratories to immediately detect, classify and quantify breast cancer cells without the need for complex set-up and calibration procedures. BreastIHC classifies cells into positively stained tumor and unstained tumor cells. One of its great advantages is its ability to differentiate between tumorous and non-tumorous structures, improving the scoring in the tumor microenvironment. "Our algorithm has proven in various tests that it works reliably under a wide range of laboratory conditions and can increase reporting speed and throughput enormously," says Faber.

The company, founded by Faber and Dr Tobias Lang, has been developing image recognition software for pathologists with the help of artificial intelligence since 2018. Partnering with several international laboratories and leading pathology service providers, Mindpeak is continuously expanding its product range and developing it into an indispensable component of the digitalised pathology workflow.


1 Chung et al. (2016), https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804149/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mindpeak GmbH
info@mindpeak.ai
Felix Faber, CEO

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dare to DeFi: DeFi Summit’s First-Ever Global Virtual Conference Brings Together Over 120 Top Industry Leaders14.6.2021 02:15:00 CEST | Press release

The largest-ever dedicated conference focused specifically on decentralized finance starts today at 9am Pacific Time. DeFi Summit is a weeklong virtual event bringing together the builders and developers that make up the decentralized finance and non-fungible token community. Free to attend, talks and presentations will be held on a broad range of topics, including DEX, wallets, DAOs, NFTs, insurance, lending, and many more. DeFi Summit 2021 Agenda: Day 1 (Monday, June 14) – The summit starts with a full day focused on NFTs. Notable speakers include digital artists Pplpleasr and Matty Mo, Max Moore of Sotheby’s, and companies including Axie Infinity, Animoca Brands and Aavegotchi. Day 2 (Tuesday, June 15) – A mystery billionaire investor is the special guestjoining Polygon Power Hour alongside Stani Kulechov from Aave, Sandeep Naiwal from Polygon and Roc Zacharias from Quickswap. Stay tuned for Coinbase, Unicrypt, Finance.Vote, and YFDAI, plus an exciting panel featuring OG DeFi VCs Le

Celltrion Healthcare presents the first real-world data for Truxima ® (biosimilar rituximab) in patients with diffuse large B-cell lymphoma at the EHA 2021 Virtual Congress12.6.2021 17:45:00 CEST | Press release

Celltrion Healthcare today presented new data from its post-approval study evaluating the real-world clinical effectiveness and safety of Truxima® (biosimilar rituximab, CT-P10) in patients with diffuse large B-cell lymphoma (DLBCL) at the European Hematology Association (EHA) 2021 Virtual Congress.1 CT-P10 was granted European Medicines Agency approval in 2017 for the treatment of rheumatoid arthritis (RA) and specific blood cancers, including non-Hodgkin’s lymphoma (NHL).2 DLBCL is the most common subtype of NHL, representing an estimated 30-40% of adult cases.3,4,5,6 This non-interventional post-authorisation safety study (PASS) involved the collection of patient-level data from hospital medical records for patients with DLBCL who received CT-P10 treatment in five European countries (United Kingdom, Spain, France, Germany and Italy). CT-P10 treatment pattern data were collected retrospectively during the 30-month observation period and patients were selected based on the treatment t

Janssen Announces Results from Phase 3 MAIA Study Showing Significant Overall Survival Benefits for Treatment with DARZALEX ® ▼ (daratumumab) in Patients with Newly Diagnosed Multiple Myeloma Who are Transplant Ineligible12.6.2021 09:01:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson announced overall survival (OS) results from the Phase 3 MAIA (NCT02252172) study showing the addition of DARZALEX® ▼(daratumumab) to lenalidomide and dexamethasone (D-Rd) resulted in a statistically significant survival benefit over lenalidomide and dexamethasone (Rd) alone in patients with newly diagnosed multiple myeloma (NDMM) who were ineligible for autologous stem cell transplant (ASCT) and were treated to progression.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing and will be presented as a late-breaking abstract during the EHA Virtual Congress (Abstract #LB1901). The prespecified interim analysis for OS found that after a median follow-up of nearly five years (56.2 months), a 32 percent reduction in the risk of death was observed in the D-Rd treatment arm vs. Rd arm.1 Median OS was not reached in either arm [hazard ratio (HR): 0.68, 95 percent confidence interval (CI),

New Phase 3 Study Results Show IMBRUVICA ® (ibrutinib)-Based Combination Regimen as an All-Oral Fixed-Duration Treatment Demonstrated Superior Progression-Free Survival in Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia12.6.2021 09:00:00 CEST | Press release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVICA® (ibrutinib) plus venetoclax (I+V) compared to chlorambucil plus obinutuzumab (Clb+O) for first-line treatment of elderly or unfit patients with chronic lymphocytic leukaemia (CLL). The study demonstrated superior progression-free survival (PFS) of a once-daily, all-oral, fixed-duration regimen of I+V versus Clb+O as first-line treatment of CLL; the study also showed improved duration of remission and significantly improved depth of remission.1 With I+V, undetectable minimal residual disease (uMRD) in peripheral blood (PB) was sustained by 85 percent of patients one year after end of treatment.1 The safety and tolerability profile of I+V was consistent with CLL treatment in an older population with comorbidities.1 These data were featured in the European Hematology Association (EHA) 2021 Virtual Press Briefing an

Alluzience ® , the first ready-to-use BoNT-A neuromodulator, receives positive decision for use in Europe11.6.2021 11:53:00 CEST | Press release

Galderma today announced that Alluzience® has completed its European decentralized procedure resulting in a positive decision for the first ready-to-use neuromodulator, a wrinkle relaxing injection, in Europe. National approvals will now take place across the region in line with local processes in each country. Designed for precision, Alluzience® is a liquid form of botulinum toxin type A intended for use in adult patients as a treatment to temporarily improve the appearance of moderate to severe glabellar lines (vertical lines between the eyebrows), when the severity of these lines has an important psychological impact on the patient.1 "The introduction of Alluzience® marks a new era in treatment innovation for upper facial lines in Europe. Like many aspects of physical appearance, glabellar lines can have a significant impact on patients’ confidence and wellbeing. I’ve heard first-hand that the transition to living and working in a virtual world has only exacerbated these issues. As

Secure Communities Forum: Behavioural Insights Can Assist Governments in the Post-Pandemic World11.6.2021 10:15:00 CEST | Press release

The Secure Communities Forum, a global collaboration of security professionals, has convened a leading panel of experts to discuss how behavioural science can impact positive social cohesion, build on the concept of positive citizenship, and encourage positive individual behaviours. The virtual event was attended by 134 people from 18 countries. The Secure Communities Forum convened the webinar in response to the ongoing Covid-19 pandemic. Governments and law enforcement agencies have used behavioural science to encourage adherence to public health measures like social distancing and mask-wearing. Lindsay Juarez, Director at Irrational Labs, USA, opened the session, offering the view that we assume humans are rational, which is not the case. She said: “Behavioural science is about setting people up for success and breaking through the noise. Information isn't enough to change behaviour, the decision-making context matters. “People don’t always act in their own long-term best interests,

Luxembourg’s Supercomputer MeluXina is Operational11.6.2021 09:18:00 CEST | Press release

Luxembourg’s high performance computer MeluXina was officially launched on June 7 putting the country on the global map of computer super powers. MeluXina is capable of executing more than 10 Petaflops, the equivalent of 10 million billion calculations per second, which will rank it among the world’s top 50 supercomputers. The petascale computer is powered by green energy and is part-funded under the European High Performance Computing Joint Undertaking. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210611005115/en/ Minister of State Xavier Bettel; His Royal Highness Henri, Grand Duke of Luxembourg; Minister of the Economy Franz Fayot; EuroHPC Joint Undertaking Executive Director Anders Jensen (Photo: Business Wire) In a series of 8 high-performance computers in the EU, MeluXina joins Vega, another petascale supercomputer located in Slovenia, as the first EuroHPC machines to go live. Its innovative modular architecture allo